The Roles of ROS Generation in RANKL-Induced Osteoclastogenesis: Suppressive Effects of Febuxostat
Open Access
- 9 April 2020
- Vol. 12 (4), 929
- https://doi.org/10.3390/cancers12040929
Abstract
Receptor activator of NF-κB ligand (RANKL), a critical mediator of osteoclastogenesis, is upregulated in multiple myeloma (MM). The xanthine oxidase inhibitor febuxostat, clinically used for prevention of tumor lysis syndrome, has been demonstrated to effectively inhibit not only the generation of uric acid but also the formation of reactive oxygen species (ROS). ROS has been demonstrated to mediate RANKL-mediated osteoclastogenesis. In the present study, we therefore explored the role of cancer-treatment-induced ROS in RANKL-mediated osteoclastogenesis and the suppressive effects of febuxostat on ROS generation and osteoclastogenesis. RANKL dose-dependently induced ROS production in RAW264.7 preosteoclastic cells; however, febuxostat inhibited the RANKL-induced ROS production and osteoclast (OC) formation. Interestingly, doxorubicin (Dox) further enhanced RANKL-induced osteoclastogenesis through upregulation of ROS production, which was mostly abolished by addition of febuxostat. Febuxostat also inhibited osteoclastogenesis enhanced in cocultures of bone marrow cells with MM cells. Importantly, febuxostat rather suppressed MM cell viability and did not compromise Dox’s anti-MM activity. In addition, febuxostat was able to alleviate pathological osteoclastic activity and bone loss in ovariectomized mice. Collectively, these results suggest that excessive ROS production by aberrant RANKL overexpression and/or anticancer treatment disadvantageously impacts bone, and that febuxostat can prevent the ROS-mediated osteoclastic bone damage.Funding Information
- Japan Society for the Promotion of Science (JP18K08329, JP16K11504, JP17H05104, JP17KK0169, JP18H06294, JP19K21382, 19K22719, 19K08839)
This publication has 42 references indexed in Scilit:
- Doxorubicin-Mediated Bone Loss in Breast Cancer Bone Metastases Is Driven by an Interplay between Oxidative Stress and Induction of TGFβPLOS ONE, 2013
- Febuxostat, an Inhibitor of Xanthine Oxidase, Suppresses Lipopolysaccharide-Induced MCP-1 Production via MAPK Phosphatase-1-Mediated Inactivation of JNKPLOS ONE, 2013
- Denosumab for the treatment of bone metastases in breast cancer: evidence and opinionTherapeutic Advances in Medical Oncology, 2011
- Crosstalk of reactive oxygen species and NF-κB signalingCell Research, 2010
- Role of mitochondrial reactive oxygen species in osteoclast differentiationAnnals of the New York Academy of Sciences, 2010
- The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trialArthritis Research & Therapy, 2010
- Review: Adjuvant bisphosphonates in endocrine-responsive breast cancer: what is their place in therapy?Therapeutic Advances in Medical Oncology, 2009
- Doxorubicin-induced reactive oxygen species generation and intracellular Ca2+increase are reciprocally modulated in rat cardiomyocytesExperimental & Molecular Medicine, 2006
- Bone Destruction in Multiple MyelomaAnnals of the New York Academy of Sciences, 2006
- New insight in the mechanism of osteoclast activation and formation in multiple myeloma: focus on the receptor activator of NF-κB ligand (RANKL)Experimental Hematology, 2004